Skip to main content
Equibles
MDLN logo

MDLN · Medline Inc.

Track MDLN — free

Use MDLN with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$36.59 +0.00 (+0.00%) At close · Sep 4
Russell 1000 member Rebalance outlook locked
Customer concentration — key customers 74% of revenue

Key customers — 74% of revenue (the year ended December 31, 2025)

“for the year ended December 31, 2025, approximately $19.7 billion (or 69% of consolidated net sales and 74% of U.S. net sales) was from sales to member hospitals under contract with our largest GPOs: Vizient Supply, LLC, HealthTrust Purchasing Group, L.P., and Premier Healthcare Alliance, L.P.”

Key customers — 69% of revenue (the year ended December 31, 2025)

“for the year ended December 31, 2025, approximately $19.7 billion (or 69% of consolidated net sales and 74% of U.S. net sales) was from sales to member hospitals under contract with our largest GPOs: Vizient Supply, LLC, HealthTrust Purchasing Group, L.P., and Premier Healthcare Alliance, L.P.”

5 customers — 11.3% of revenue (the year ended December 31, 2025)

“For the year ended December 31, 2025, our top five U.S. customers represented approximately $3.2 billion (or 11.3%) of our net sales.”
View the 10-K filed Feb 25, 2026
Market Cap
$48.11B
Shares
1.31B

MDLN metrics

68 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$36.59
Market cap
$48.11B

Price action

19 metrics
Price change (1W)
+3.7%
Price change (30D)
+8.2%
Price change (3M)
+8.9%
Price change (6M)
-16.5%
Price change (YTD)
-12.9%
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
45.8%
Beta
0.6
RSI (14D)
53.0
Price vs SMA 50
-3.2%
Price vs SMA 200
—
Avg volume (3M)
7.78M
Relative volume
0.7
Average dollar volume
$289.67M

Company

3 metrics
Sector
Healthcare
Industry
Medical Instruments & Supplies
Shares outstanding
1.31B

Valuation

12 metrics
P / E (TTM)
44.6
Trailing earnings · reciprocal yield 2.2%
PEG ratio
—
EV / revenue
1.9×
reciprocal yield 51.6%
EV / EBITDA
20.4×
reciprocal yield 4.9%
EV / EBIT
31.9×
reciprocal yield 3.1%
P / sales
1.6×
reciprocal yield 62.2%
P / book
4.2
reciprocal yield 24.1%
FCF yield
3.2%
TTM · current market cap
Buyback yield
0.0%
P / FCF
31.1
reciprocal yield 3.2%
P / operating cash flow
24.1
reciprocal yield 4.1%
Earnings yield
2.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
26.2%
Operating margin
6.1%
Trailing 12 months
Net margin
4.1%
Gross profit (TTM)
$7.84B
Operating profit (TTM)
$1.82B
Net income (TTM)
$1.08B
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
5.2%
Effective tax rate
18.3%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+11.6%
Year over year
Net income growth YoY
-57.8%
Revenue (TTM)
$29.94B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
—
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
9.6%
Return on assets
2.8%
Debt / equity
1.1
Current ratio
4.3
EBITDA (TTM)
$2.84B
Free cash flow (TTM)
$1.55B
Quick ratio
2.6
Interest coverage
2.3
Net debt / EBITDA
3.5
Return on invested capital
6.9%
Trailing 12 months
Net cash
−$9.90B
Latest balance sheet
Cash & equivalents
$2.33B
Total assets
$39.35B
Total debt
$12.58B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$1.99B
Capital expenditures (TTM)
$446.00M
R&D (TTM)
—
SG&A (TTM)
$4.90B
Stock compensation (TTM)
$94.00M
R&D / revenue
—
Stock compensation / revenue
0.3%

Ownership (13F)

3 metrics
13F filers
405
13F filer change QoQ
+91
Institutional ownership
57.3%

Short interest

3 metrics
Short interest
2.8%
Latest settlement · 3.8 days to cover
Days to cover
3.8d
Short-squeeze score
59 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$161.93M
Insider-sentiment score
20 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 2046386 CUSIP 58507V107 13F (30d) 244 filings 244 filers Visit website Investor relations